Becton, Dickinson and Co. (NYSE:BDX)
CAPS Rating:
Becton Dickinson makes all sorts of medical devices and instruments, including scalpels, syringes, and diagnostic equipment.
Growing the love for investing
Becton Dickinson makes all sorts of medical devices and instruments, including scalpels, syringes, and diagnostic equipment.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Becton, Dickinson, & Company (BDX), founded in 1897, is a rock solid, wide moat company in the healthcare industry that makes surgical tools, needles, and other medical products. I see today’s current healthcare fears as a great opportunity to be greedy and buy this wonderful business at a fair-to-cheap price.
Over the 5 years, BDX has averaged very impressive 17% annual returns on capital. (89th percentile) Over past 10 years, BDX never returned less than 11% returns on capital. (11% in 2004) BDX has grown earnings at a 10yr avg of 14.2% and successfully grew earnings 9 out of the past 10 years. (2004 being the only down year) Free cash flow has grown at 9.5% compounded over the past decade.
I’ll conservatively forecast EPS growth at 9% per yr (40% lower BDX's 10 yr avg) over the next 3-5 years. Adding in 2% per year in reinvested dividends, I’m expecting 11% compounded annual returns going forward, assuming P/E remains about the same.
BDX is currently selling at 14x earnings, and more importantly, 14x free cash flow. I think that’s a great price for this 115 year old company with a bright future.
Becton, Dickinson, & Company (BDX), has prospered through two World Wars, the Great Depression, about 15 recessions, and emerged from it all as a top company. I don't think Obamacare or this recession is going to be the end of that success. Outperform.